Literature DB >> 12205742

A case of intravenous immunoglobulin-resistant Kawasaki disease treated with methotrexate.

Mi Seon Lee1, Seon Young An, Gwang Cheon Jang, Dong Soo Kim.   

Abstract

Kawasaki disease, an acute febrile vasculitis of unknown etiology, is usually treated with high doses of immunoglobulin (IVIG) and aspirin. However, 20% of children show persistent or recurrent fever despite IVIG, and coronary artery aneurysm progression. In such cases of resistance to IVIG treatment, repeated IVIG administration or the initiation of steroid therapy, and the use of cyclophosphamide have been reported. We aimed to show in this study that methotrexate (MTX) may be used as a treatment for Kawasaki disease resistant to IVIG treatment. We report the case of a 6-year old boy who was admitted at another hospital with an initial complaint of a fever for 5 days and skin rashes for 3 days. The patients fever persisted despite three courses of IVIG (2 gm/kg, 1 gm/kg, 1 gm/kg, respectively) over a 14-day period. On day 14 of his illness he showed a dilated right coronary artery, and on day 19 dexamethasone, at a daily dose of 0.3 mg/kg, was given but this resulted in defervescence. However, upon stopping the dexamethasone treatment, his fever recurred and he was transferred to our hospital. On days 31 and 38 of his illness, IVIG (400 mg/kg for 5 days, twice) was administered and from day 38 onwards the patient was given dexamethasone (0.6 mg/kg, daily) and MTX (10 mg/BSA, once weekly) whereupon his fever subsided and did not recur. On day 48 dexamethasone was replaced with prednisolone, which was subsequently tapered. The patient is now taking MTX and being observed on an outpatient basis. We report the case of a boy with IV-globulin resistant Kawasaki disease, who after repeated infusions of IVIG and steroid therapy showed fever recurrence, which that subsided after MTX treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12205742     DOI: 10.3349/ymj.2002.43.4.527

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  11 in total

1.  A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease.

Authors:  Koichi Sakata; Kenji Hamaoka; Sei-Ichiro Ozawa; Ayumi Niboshi; Takao Yoshihara; Tesuo Nishiki; Yumi Nakagawa; Kikuko Kazuta; Yoshiko Morimoto; Yasutaka Kamiya; Toru Yamamoto; Yoshihiro Horii; Sachiko Kido
Journal:  Eur J Pediatr       Date:  2007-06       Impact factor: 3.183

Review 2.  Overview of Pharmacological Treatment Options for Pediatric Patients with Refractory Kawasaki Disease.

Authors:  Seyyedeh Saneeymehri; Katherine Baker; Tsz-Yin So
Journal:  J Pediatr Pharmacol Ther       Date:  2015 May-Jun

Review 3.  Kawasaki disease: etiopathogenesis and novel treatment strategies.

Authors:  Shreya Agarwal; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2016-09-13       Impact factor: 4.473

Review 4.  Kawasaki disease.

Authors:  Dong Soo Kim
Journal:  Yonsei Med J       Date:  2006-12-31       Impact factor: 2.759

5.  A case of refractory Kawasaki disease complicated by peripheral ischemia.

Authors:  Na Yeon Kim; Deok Young Choi; Mi Jin Jung; In-Sang Jeon
Journal:  Pediatr Cardiol       Date:  2008-05-15       Impact factor: 1.655

Review 6.  Refractory Kawasaki disease: diagnostic and management challenges.

Authors:  Sophie Duignan; Sarah L Doyle; Colin J McMahon
Journal:  Pediatric Health Med Ther       Date:  2019-10-30

7.  Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.

Authors:  Taek Jin Lee; Ki Hwan Kim; Jin-Kyong Chun; Dong Soo Kim
Journal:  Yonsei Med J       Date:  2008-10-31       Impact factor: 2.759

8.  Catastrophic Kawasaki disease unresponsive to IVIG in a 3-month-old infant: a diagnostic and therapeutic challenge.

Authors:  Cristina Medeiros Ribeiro de Magalhães; Natália Ribeiro de Magalhães Alves; Adriana Valença de Melo; Clodoaldo Abreu da Silveira Junior; Yanna Karla de Medeiros Nόbrega; Lenora Gandolfi; Riccardo Pratesi
Journal:  Pediatr Rheumatol Online J       Date:  2012-08-28       Impact factor: 3.054

9.  Clinical outcome of patients with refractory Kawasaki disease based on treatment modalities.

Authors:  Hyun Jung Kim; Hyo Eun Lee; Jae Won Yu; Hong Ryang Kil
Journal:  Korean J Pediatr       Date:  2016-08-24

10.  Clinical Outcomes of Low-Dose Methotrexate Therapy as a Second-Line Drug for Intravenous Immunoglobulin-Resistant Kawasaki Disease.

Authors:  Hyejin Jang; Kyu Yeun Kim; Dong Soo Kim
Journal:  Yonsei Med J       Date:  2018-01       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.